China’s CARsgen raises $30M for CAR-T work

John Carroll
Shanghai-based Therapeutics has rounded up a $ 30 million B round to advance its on CAR-T therapies. The biotech has been working on personalized CAR-T programs, reengineering T cells from patients and turning them into cancer attack weapons.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS